No Data
No Data
Unveiling 4 Analyst Insights On Genelux
Genelux (NASDAQ:GNLX) underwent analysis by 4 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.Summarizing their recent assessments, the table below illustrates
Genelux Is Maintained at Speculative Buy by Benchmark
Genelux Is Maintained at Speculative Buy by Benchmark
Genelux Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/31/2024 832.84% Benchmark $30 → $25 Maintains Speculative Buy 05/13/2024 1094.03% HC Wainwright & Co. →
Express News | Genelux Corp : Benchmark Cuts Target Price to $25 From $30
12 Health Care Stocks Moving In Monday's Pre-Market Session
GainersCue Health (NASDAQ:HLTH) stock moved upwards by 32.4% to $0.12 during Monday's pre-market session. The market value of their outstanding shares is at $19.8 million. SCWorx (NASDAQ:WORX) shares
Top Midday Decliners
Verastem Oncology (VSTM) reported a phase 1/2 clinical trial evaluating avutometinib and defactinib in combination with gemcitabine and nab-paclitaxel in 41 patients with metastatic pancreatic cancer
No Data